secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134749
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control
--------------------------------------------------------------------------------

- 30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).
- Onvansertib well-tolerated; no major or unexpected toxicities at either dose.
- Additional CRDF-004 clinical data expected in 1H 2025.
- Conference call held Dec 10, 2024 at 8:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/0000950170-24-134749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/crdf-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer